As of Friday, December 19, Cassava Sciences, Inc.’s SAVA share price has dipped by 17.37%, which has investors questioning if this is right time to buy.
Canaccord analyst Kyle Mikson raised the firm’s price target on Caris Life Sciences (CAI) to $30 from $28 and keeps a Hold rating on the shares.
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
TipRanks on MSN
Sight Sciences price target raised to $12 from $7 at UBS
UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback